ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shot up 5.8% on Monday . The stock traded as high as $3.32 and last traded at $3.27. 1,750,000 shares were traded during trading, an increase of 27% from the average session volume of 1,375,827 shares. The stock had previously closed at $3.09.

Several brokerages have weighed in on ZIOP. BidaskClub cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 26th. JPMorgan Chase & Co. cut ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a research note on Monday, June 18th. Finally, ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $5.25.

The company has a market cap of $465.58 million, a P/E ratio of -5.96 and a beta of 1.39.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). equities research analysts expect that ZIOPHARM Oncology Inc. will post -0.5 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its stake in shares of ZIOPHARM Oncology by 3.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 664,222 shares of the biotechnology company’s stock valued at $2,604,000 after buying an additional 19,580 shares during the last quarter. MetLife Investment Advisors LLC grew its stake in shares of ZIOPHARM Oncology by 77.1% during the second quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 28,734 shares during the last quarter. Raymond James & Associates grew its stake in shares of ZIOPHARM Oncology by 168.3% during the second quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 36,568 shares during the last quarter. Northern Trust Corp grew its stake in shares of ZIOPHARM Oncology by 2.7% during the second quarter. Northern Trust Corp now owns 1,623,297 shares of the biotechnology company’s stock valued at $4,902,000 after buying an additional 42,905 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of ZIOPHARM Oncology by 25.8% during the first quarter. Wells Fargo & Company MN now owns 251,068 shares of the biotechnology company’s stock valued at $985,000 after buying an additional 51,499 shares during the last quarter. 39.29% of the stock is currently owned by hedge funds and other institutional investors.

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Article: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.